首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1983156

胸膜炎治疗市场：按治疗方法、症状、患者类型、医疗机构、分销管道、最终用户和地区划分

Pleurodynia Treatment Market, By Treatment Modality, By Symptoms, By Patient Type, By Healthcare Setting, By Distribution Channel, By End User, By Geography

出版日期: 2026年02月11日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2026 年，胸膜炎治疗市场规模将达到 1.611 亿美元，到 2033 年将达到 2.4064 亿美元。预计从 2026 年到 2033 年，该市场将以 5.9% 的复合年增长率成长。

报告范围		报告详情
基准年：	2025	2026年市场规模：	1.611亿美元
历史数据时期：	2020年至2024年	预测期：	2026年至2033年
2026年至2033年预测期间的复合年增长率：	5.90%	2033年市场规模预测：	2.4064亿美元

胸膜炎（俗称流行性肌肉痛或博恩霍尔姆病）是一种主要由克沙奇病毒B引起的病毒感染疾病，其特征是严重的胸部和上腹部疼痛，症状类似心臟和肺部疾病。这种急性发烧疾病主要影响儿童和青少年，表现为胸壁肌肉和膈肌的剧烈、间歇性疼痛，常伴随发烧、头痛和不适。全球胸膜炎治疗市场涵盖了旨在治疗疾病的药物干预、支持疗法和诊断解决方案。胸膜炎可自行消退，但会显着损害身体机能。

治疗通讯协定通常包括症状治疗，使用止痛药、抗发炎药，重症患者则使用抗病毒药物。支持性照护包括休息、补充液体和必要的呼吸支持。随着人们对肠病毒感染疾病的认识不断提高、诊断能力不断提升以及标靶治疗方法的研发，市场环境正在改变。肠病毒感染与其他呼吸系统和心臟疾病的症状重迭，为医疗专业人员的准确诊断带来了挑战，也推动了对先进诊断工具和治疗通讯协定的需求。病毒爆发的日益增多，以及发展中地区医疗基础设施的改善，持续影响全球市场动态和治疗可近性。

市场动态

全球胸膜炎治疗市场正经历显着成长，这主要得益于医护人员和患者对肠病毒感染疾病的认识不断提高。这提高了诊断率，并相应地增加了治疗需求。病毒爆发的发生率不断上升，尤其是在学校和军事设施等人员密集的场所，持续推高了对有效治疗性介入的市场需求。诊断能力的提升，包括先进的分子检测和照护现场技术，能够快速识别病原体，有助于及时启动治疗，并推动市场扩张。

新兴经济体医疗保健成本的不断上涨，以及抗病毒药物和疼痛管理疗法的可近性提高，正在推动不同地区市场的成长。然而，胸膜炎通常会自行消退，且往往无需特殊治疗，这可能限制了药物干预的需求，从而对市场构成重大限制。此外，由于胸膜炎的症状与心肺疾病相似，误诊仍是一个主要挑战，导致不当的治疗通讯协定和市场效率低下。基层医疗医师对鑑别诊断技术的认识不足，可能导致病例漏报和不恰当的治疗方法。此外，缺乏针对某些肠病毒株的特异性抗病毒疗法也限制了治疗选择和市场潜力。

儘管面临这些挑战，但针对特定肠病毒作用机制的新型抗病毒化合物的研发，有望带来突破性的治疗方法。远端医疗平台的扩展为远距会诊和监测提供了契机，这在疫情爆发期间尤其重要。投资研发快速诊断工具蕴藏着巨大的市场机会。特别是，能够区分胸膜炎与其他胸痛病因的就地检验解决方案，有望最终改善患者预后并加速市场渗透。

本次调查的主要特点。

本报告对全球胸膜炎治疗市场进行了详细分析，显示了以 2025 年为基准年，预测期（2026-2033 年）的市场规模和复合年增长率（%）。
本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本报告根据以下参数对全球胸膜炎治疗市场的主要企业参与者进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
透过利用本报告中提出的见解，企业行销负责人和经营团队将能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
相关人员可以透过利用分析全球胸膜炎治疗市场中使用的各种策略矩阵来简化决策过程。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 南非
- 北非
- 中非

第十一章竞争格局

AbbVie Inc
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Company
Cipla Ltd
Reddy's Laboratories Ltd
Hoffmann La Roche Ltd
GlaxoSmithKline plc
Johnson &Johnson
Merck &Co., Inc
Novartis AG
Pfizer Inc
Sanofi SA
Sun Pharmaceutical Industries Ltd

第十二章分析师建议

机会
分析师意见
Coherent Opportunity Map

第十三章参考文献与调查方法

参考
调查方法
关于本公司

简介目录

Product Code: CMI9323

Pleurodynia Treatment Market is estimated to be valued at USD 161.1 Mn in 2026 and is expected to reach USD 240.64 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 161.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.90%	2033 Value Projection:	USD 240.64 Mn

Pleurodynia, commonly referred to as epidemic myalgia or Bornholm disease, represents a viral infection primarily caused by Coxsackievirus B, characterized by intense chest and upper abdominal pain that mimics cardiac or pulmonary conditions. This acute febrile illness predominantly affects children and young adults, presenting with sharp, intermittent pain in the chest wall muscles and diaphragm, often accompanied by fever, headache, and malaise. The global pleurodynia treatment market encompasses pharmaceutical interventions, supportive care therapies, and diagnostic solutions aimed at managing this self-limiting yet debilitating condition.

Treatment protocols typically involve symptomatic management through analgesics, anti-inflammatory medications, and antiviral agents in severe cases, while supportive measures include rest, hydration, and respiratory support when necessary. The market landscape is evolving with increased awareness of enteroviral infections, improved diagnostic capabilities, and the development of targeted therapeutic approaches. Healthcare providers face challenges in accurate diagnosis due to symptom overlap with other respiratory and cardiac conditions, driving demand for enhanced diagnostic tools and treatment protocols. The growing incidence of viral outbreaks, coupled with improved healthcare infrastructure in developing regions, continues to shape market dynamics and treatment accessibility globally.

Market Dynamics

The global pleurodynia treatment market experiences significant growth driven by increasing awareness about enteroviral infections among healthcare professionals and patients, leading to improved diagnosis rates and subsequent treatment demand. Rising incidence of viral outbreaks, particularly in crowded environments such as schools and military facilities, creates sustained market demand for effective therapeutic interventions. Enhanced diagnostic capabilities, including advanced molecular testing and point-of-care diagnostics, enable faster identification of causative agents, promoting timely treatment initiation and driving market expansion.

Growing healthcare expenditure in emerging economies, coupled with improved access to antiviral medications and pain management therapies, contributes to market growth across diverse geographical regions. However, the market faces substantial restraints including the self-limiting nature of pleurodynia, which often resolves without specific treatment, potentially limiting pharmaceutical intervention requirements. Misdiagnosis remains a significant challenge due to symptom similarity with cardiac and pulmonary conditions, leading to inappropriate treatment protocols and market inefficiencies. Limited awareness among primary care physicians about differential diagnosis techniques may result in underreporting and suboptimal treatment approaches. Additionally, the absence of specific antiviral therapies for certain enteroviral strains constrains treatment options and market potential.

Despite these challenges, opportunities emerge through development of novel antiviral compounds targeting specific enteroviral mechanisms, creating potential for breakthrough therapies. Expanding telemedicine platforms offer opportunities for remote consultation and monitoring, particularly valuable in outbreak scenarios. Investment in research and development for rapid diagnostic tools presents significant market opportunities, especially for point-of-care testing solutions that can differentiate pleurodynia from other chest pain etiologies, ultimately improving patient outcomes and market penetration.

Key Features of the Study

This report provides in-depth analysis of the global pleurodynia treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pleurodynia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie Inc, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Ltd, Dr. Reddy's Laboratories Ltd, F. Hoffmann La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc, Novartis AG, Pfizer Inc, Sanofi S.A, and Sun Pharmaceutical Industries Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pleurodynia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleurodynia treatment market

Market Segmentation

Treatment Modality Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmacological Therapies
- Analgesics
- Non Steroidal Anti Inflammatory Drugs (NSAIDs)
- Antiviral Agents
- Muscle Relaxants
- Corticosteroids
- Non Pharmacological Therapies
- Physical Therapy
- Pain Management Procedures
- Supportive Care (Rest, Hydration)
- Combination Therapies
- Pharmacological + Non Pharmacological
Symptoms Insights (Revenue, USD Mn, 2021 - 2033)
- Chest Pain
- Fever
- Cough
- Headache
- Sore Throat
- Muscular Aches and Pains
Patient Type Insights (Revenue, USD Mn, 2021 - 2033)
- Adult
- Geriatric
- Pediatric
Healthcare Setting Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital
- Ambulatory/Outpatient Clinics
- Home Healthcare
Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Mn, 2021 - 2033)
- Healthcare Providers
- Hospitals
- Clinics
- Patients/Consumers
Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie Inc
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Company
- Cipla Ltd
- Reddy's Laboratories Ltd
- Hoffmann La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc
- Sanofi S.A
- Sun Pharmaceutical Industries Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Pleurodynia Treatment Market, By Treatment Modality
- Global Pleurodynia Treatment Market, By Symptoms
- Global Pleurodynia Treatment Market, By Patient Type
- Global Pleurodynia Treatment Market, By Healthcare Setting
- Global Pleurodynia Treatment Market, By Distribution Channel
- Global Pleurodynia Treatment Market, By End User
- Global Pleurodynia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Pleurodynia Treatment Market, By Treatment Modality, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Analgesics
  - Non Steroidal Anti Inflammatory Drugs (NSAIDs)
  - Antiviral Agents
  - Muscle Relaxants
  - Corticosteroids
Non Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Physical Therapy
  - Pain Management Procedures
  - Supportive Care (Rest, Hydration)
Combination Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  - Pharmacological + Non Pharmacological

5. Global Pleurodynia Treatment Market, By Symptoms, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Fever
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Cough
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Headache
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Sore Throat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Muscular Aches and Pains
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Pleurodynia Treatment Market, By Patient Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Pleurodynia Treatment Market, By Healthcare Setting, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Ambulatory/Outpatient Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Home Healthcare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Pleurodynia Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

9. Global Pleurodynia Treatment Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Healthcare Providers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Patients/Consumers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

10. Global Pleurodynia Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Modality, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Symptoms, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Healthcare Setting, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

12. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

13. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

胸膜炎治疗市场：按治疗方法、症状、患者类型、医疗机构、分销管道、最终用户和地区划分

Pleurodynia Treatment Market, By Treatment Modality, By Symptoms, By Patient Type, By Healthcare Setting, By Distribution Channel, By End User, By Geography

市场动态

目录

第一章：研究目标与前提条件

第二章市场范围

第三章：市场动态、监管与趋势分析

第四章全球胸膜炎治疗市场：依治疗方法，2021-2033年

第五章全球胸膜炎治疗市场：依症状划分，2021-2033年

第六章全球胸膜炎治疗市场：依病患类型划分，2021-2033年

第七章全球胸膜炎治疗市场：依医疗机构划分，2021-2033年

第八章全球胸膜炎治疗市场：依通路划分，2021-2033年

第九章全球胸膜炎治疗市场：依最终用户划分，2021-2033年

第十章全球胸膜炎治疗市场：依地区划分，2021-2033年